Insulin (generic), Humulin, Novolin

Insulin (generic), Humulin, Novolin Newswire

Comprehensive Real-Time News Feed for Insulin (generic), Humulin, Novolin.

Results 1 - 20 of 6,728 in Insulin (generic), Humulin, Novolin

  1. Yale U Scientists Experiment With Watered-Down Version Of DNP To Reverse Type 2 DiabetesRead the original story w/Photo

    1 hr ago | International Business Times

    Scientists at Yale University are experimenting with a watered-down version of the chemical mitochondrial protonophore 2, 4-dinitrophenol to reverse Type 2 diabetes. The result of their trial on mice, published in the Science journal On Feb 26, found that low-dose infusion of DNP that was a hundred times lower than toxic levels reduce blood glucose significantly and insulin concentrations in a model of a rodent with Type 2 diabetes.

    Comment?

  2. Europ Continents brings diabetes prevention device to marketRead the original story w/Photo

    1 hr ago | Pnompenh Post

    Post Plus reporter Kali Kotoski wired up on the ANS1 testing device. Luckily all signals are on "green".

    Comment?

  3. Insulet (PODD) Releases Earnings Results, Misses Expectations By $0.06 EPSRead the original story

    1 hr ago | AmericanBankingNews.com

    Insulet posted its quarterly earnings results on Thursday. The company reported earnings per share for the quarter, missing the consensus estimate of by $0.06, Analyst Ratings Network.com reports.

    Comment?

  4. Sanofi Gains U.S. Approval for Successor to LantusRead the original story

    2 hrs ago | The Washington Post

    Toujeo, a long-acting form of insulin to help control blood sugar, was cleared by the Food and Drug Administration for use in adults with Type 1 and Type 2 diabetes, Sanofi said in a statement. The treatment is expected to be available in April, the company said.

    Comment?

  5. Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common StockRead the original story

    3 hrs ago | Sys-Con Media

    All of the shares of common stock to be sold in the offering are being offered by Tandem. In addition, Tandem has granted the underwriters a 30-day option to purchase up to an additional 787,500 shares of common stock.

    Comment?

  6. FDA Approves Sanofi's Insulin DrugRead the original story w/Photo

    3 hrs ago | International Business Times

    Sanofi has won approval from United States health regulators for its diabetes treatment Toujeo. The drug is a successor to the French drugmaker's top selling product Lantus, which loses patent protection in 2015, Bloomberg reports .

    Comment?

  7. Secret health benefits of sunshineRead the original story w/Photo

    4 hrs ago | The New Zealand Herald

    Summer sunshine makes most of us feel better, but there may be more to the benefits than just feeling good. A growing body of evidence suggests sunlight itself - with adequate protection, of course - may actually be good for health.

    Comment?

  8. Promising New Method May Reverse Type 2 Diabetes: YaleRead the original story w/Photo

    6 hrs ago | News Max

    Yale University researchers have developed an experimental pill that reversed Type 2 diabetes and fatty liver disease in rats, and may hold promise for people, too. The Yale study, published in the journal Science , opens the door to a new way to treat the root cause of diabetes - as well as the related conditions known as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis .

    Comment?

  9. New diabetes medicine might save drugmakerRead the original story w/Photo

    7 hrs ago | WPTV Local News

    A new diabetes drug was approved by the Food and Drug Administration Wednesday. It doesn't sound like breaking news, but for the company behind the drug, it's a pretty big deal.

    Comment?

  10. Sanofi diabetes drug awaits imminent EU green lightRead the original story

    9 hrs ago | WNFL-AM Green Bay

    Sanofi's new Toujeo diabetes drug is on track to receive a potential green light from European regulators this week, building on a U.S. regulatory approval awarded on Wednesday. Toujeo is a more potent follow-up to the French drugmaker's top-selling Lantus insulin product, which accounts for a fifth of group sales, and the new drug is pivotal to Sanofi's diabetes business as Lantus faces loss of patent protection.

    Comment?

  11. Type 2 diabetes, fatty liver disease reversed in ratsRead the original story w/Photo

    9 hrs ago | Science Daily

    A controlled-release oral therapy has been developed by scientists that reversed type 2 diabetes and fatty liver disease in rats, according to a study. "Given these promising results in animal models of NAFLD/NASH and type 2 diabetes we are pursuing additional preclinical safety studies to take this mitochondrial protonophore approach to the clinic" said the researchers.

    Comment?

  12. Once-Daily Basal Insulin Toujeo Wins FDA NodRead the original story

    9 hrs ago | P&T Community

    The FDA has approved Toujeo , a once-daily long-acting basal insulin, to improve glycemic control in adults with type-1 and type-2 diabetes. The product is expected to be available in the U.S. at the beginning of the second quarter, 2015.

    Comment?

  13. Researchers reverse type 2 diabetes and fatty liver disease in ratsRead the original story w/Photo

    9 hrs ago | PhysOrg Weblog

    Yale researchers developed a controlled-release oral therapy that reversed type 2 diabetes and fatty liver disease in rats, according to a study published on Feb. 26 by Science . Existing therapies for type 2 diabetes , and the closely associated conditions of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , have had limited success at treating the root causes of these diseases.

    Comment?

  14. GLP-1 secretion is reduced in overweight, pre-diabetes and type 2 diabetesRead the original story

    10 hrs ago | Science Daily

    The world's largest study looking at the secretion of the gut hormone GLP-1 has found that the secretion is reduced among overweight and obese people, people with pre-diabetes and newly diagnosed people with type 2 diabetes. GLP-1 is a hormone that regulates glucose levels in the body by stimulating the secretion of insulin, and GLP-1 also inhibits appetite.

    Comment?

  15. Mushroom extracts show blood sugar management potential: StudyRead the original story w/Photo

    19 hrs ago | NutraIngredients-USA

    Powdered preparations of the mushrooms Pleurotus ostreatus and Pleurotus cystidiosus may reduce blood sugar levels after a meal in healthy people, while also impacting insulin levels in diabetics, says a new study. Suspensions of freeze dried and powdered P. ostreatus and P. cystidiosus may influence the activity of an enzyme called glucokinase, an important sensor of glucose levels in the body, report scientists from the University of Sri Jayewardenepura and the University of Colombo, Sri Lanka.

    Comment?

  16. [Report] Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in ratsRead the original story

    Wednesday | Science

    Nonalcoholic fatty liver disease is a major factor in the pathogenesis of type 2 diabetes and non-alcoholic steatohepatitis . The mitochondrial protonophore 2,4 dinitrophenol has beneficial effects on NAFLD, insulin resistance, and obesity in preclinical models but is too toxic for clinical use.

    Comment?

  17. Social Support: New Bedford man uses Facebook pages to connect weight loss surgery patientsRead the original story w/Photo

    Saturday Feb 21 | SouthCoastToday.com

    A local man who successfully underwent bariatric surgery is using modern technology and social media to share his experience and to support others who are considering or who have undergone weight loss surgery as they continue their journey to a healthier life after struggling with obesity and related health problems for many years. New Bedford resident Donald Manley established two online Facebook support groups where individuals can discuss personal issues, ask questions, share advice and offer bariatric-friendly recipes.

    Comment?

  18. Lilly plans to introduce biosimilar Lantus in Europe in MayRead the original story

    11 hrs ago | Indianapolis Business News

    Eli Lilly and Co. plans to introduce its biosimilar copy of Sanofi's Lantus insulin for diabetes in Europe in May, when the patent expires in most markets.

    Comment?

  19. Have type 2 diabetes? Exercise after dinnerRead the original story w/Photo

    11 hrs ago | Battle Diabetes

    A new study from the University of Missouri found that people with type 2 diabetes can reduce their risks of cardiovascular disease and lower their blood sugar levels if they exercise after dinner, instead of before. "Results from this study show that resistance exercise has its most powerful effect on reducing glucose and fat levels in one's blood when performed after dinner," said study author Jill Kanaley, professor in the Nutrition and Exercise Physiology Department at MU.

    Comment?

  20. NAPSR News: Sanofi receives FDA approval for once-daily basal insulin ToujeoRead the original story

    13 hrs ago | PR Log

    PRLog - Feb. 26, 2015 - WASHINGTON -- The U.S. Food and Drug Administration has approved Sanofi's ToujeoA , a once-daily long-acting basal insulin, intended to improve the glycemic index in adults living with type 1 and type 2 diabetes. "Sanofi is proud of its long heritage in diabetes and insulin therapies, including LantusA which has supported patients in the management of their diabetes for more than a decade.

    Comment?